Not that it matters now, but the August 2023 plan didn't collect any CP data until the 2030s. It was purely focused on anticancer activity until Phase 3.
You are right that AML will be running behind the CPACS trial and that it won't treat the first patient until H1 2025.
RAC Price at posting:
$1.66 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)